Abstract
In a fraction of SARS-CoV-2 infected individuals treated with the oral antiviral Paxlovid, the virus rebounds following treatment. The mechanism driving rebound is not understood. Here, we show that viral dynamic models based on the hypothesis that Paxlovid treatment near the time of symptom onset halts the depletion of target cells, but may not fully eliminate the virus, which can lead to viral rebound. We also show that the occurrence of viral rebound is sensitive to model parameters, and the time treatment is initiated, which may explain why only a fraction of individuals develop viral rebound. Finally, the models are used to test the therapeutic effects of two alternative treatment schemes. These findings also provide a possible explanation for rebounds following other antiviral treatments for SARS-CoV-2.
Significance Paxlovid is an effective treatment for SARS-CoV-2. In some patients treated with Paxlovid, the initial reduction in viral load is followed by a rebound once treatment is stopped. Understanding the mechanisms of the rebound may help us develop better treatment strategies to minimize this possibility. We hypothesize that early treatment with Paxlovid stops viral growth, but may not fully clear the virus, thus preserving host resources that would have otherwise been used by the virus. Once treatment ends, the remaining viruses can utilize the available resources to grow, leading to the observed transient viral rebound. We built standard viral dynamic models based on this hypothesis and fit the models to data to show its feasibility. We further examined the effect of two alternative treatment schemes.
Competing Interest Statement
ASP owns stock in Pfizer. He was also on a Pfizer advisory committee and received an honorarium. The other authors declare that they have no competing interests.
Funding Statement
This work was performed under the auspices of the US Dept. of Energy under contract 89233218CNA000001 and supported by National Institutes of Health grant R01-OD011095 (ASP) National Institutes of Health grant R01-AI116868 (RMR) National Institutes of Health grant U54-HL143541-04 (RMR) Los Alamos National Laboratory LDRD 20200743ER, 20200695ER, and 20210730ER.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data that were originally reported by M. E. Charness et al., Rebound of SARS CoV 2 Infection after Nirmatrelvir Ritonavir Treatment. N. Engl. J. Med. 387, 1045-1047 (2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
There are no original data underlying this work. Only previously published data were used for this study by Charness et al. (2022). The viral load values used in this study are given in the Supplementary Materials. M. E. Charness et al., Rebound of SARS CoV 2 Infection after Nirmatrelvir Ritonavir Treatment. N. Engl. J. Med. 387, 1045-1047 (2022).
